Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with CRT in locally-advanced SCCHN
NCT02586207Phase 1Completed
- Sponsor
- Sanford Health
- Start
- Nov 2015
- Primary completion
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sanford Health. Primary endpoint: Adverse Events at Day 240. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02586207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586207.